CN116694568A - 用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法 - Google Patents

用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法 Download PDF

Info

Publication number: CN116694568A
Authority: CN; China
Prior art keywords: cells; cell; tumor; wast; effector cells
Prior art date: 2022-03-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN202211690866.0A

Other languages

English (en)

Chinese (zh)

Inventor

苏盛

黄劲松

于和鸣

宋亚丽

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Beijing Xibo Biomedical Technology Co ltd

Original Assignee

Beijing Xibo Biomedical Technology Co ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2022-03-02

Filing date

2022-03-02

Publication date

2023-09-05

2022-03-02 Application filed by Beijing Xibo Biomedical Technology Co ltd filed Critical Beijing Xibo Biomedical Technology Co ltd

2022-03-02 Priority to CN202211690866.0A priority Critical patent/CN116694568A/zh

2023-09-05 Publication of CN116694568A publication Critical patent/CN116694568A/zh

Status Pending legal-status Critical Current

Links

230000000259 anti-tumor effect Effects 0.000 title claims abstract description 13
239000000556 agonist Substances 0.000 title abstract description 26
238000000034 method Methods 0.000 title abstract description 18
239000012642 immune effector Substances 0.000 title abstract description 15
229940121354 immunomodulator Drugs 0.000 title abstract description 15
239000000203 mixture Substances 0.000 title abstract description 14
238000009472 formulation Methods 0.000 title abstract description 13
230000003213 activating effect Effects 0.000 title abstract description 7
210000000987 immune system Anatomy 0.000 title abstract description 6
210000004027 cell Anatomy 0.000 claims abstract description 212
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims abstract description 16
229930192851 perforin Natural products 0.000 claims abstract description 16
102000001398 Granzyme Human genes 0.000 claims abstract description 15
108060005986 Granzyme Proteins 0.000 claims abstract description 15
239000012636 effector Substances 0.000 claims description 76
206010028980 Neoplasm Diseases 0.000 claims description 49
238000002360 preparation method Methods 0.000 claims description 26
210000001744 T-lymphocyte Anatomy 0.000 claims description 12
206010006187 Breast cancer Diseases 0.000 claims description 8
208000026310 Breast neoplasm Diseases 0.000 claims description 8
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 claims description 5
201000007270 liver cancer Diseases 0.000 claims description 5
208000014018 liver neoplasm Diseases 0.000 claims description 5
210000000581 natural killer T-cell Anatomy 0.000 claims description 5
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
201000005202 lung cancer Diseases 0.000 claims description 4
208000020816 lung neoplasm Diseases 0.000 claims description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 16
102000004503 Perforin Human genes 0.000 abstract description 14
108010056995 Perforin Proteins 0.000 abstract description 14
239000000427 antigen Substances 0.000 abstract description 14
108091007433 antigens Proteins 0.000 abstract description 14
102000036639 antigens Human genes 0.000 abstract description 14
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 abstract description 12
238000000338 in vitro Methods 0.000 abstract description 10
229910000073 phosphorus hydride Inorganic materials 0.000 abstract description 6
230000000694 effects Effects 0.000 abstract description 5
210000004881 tumor cell Anatomy 0.000 abstract description 5
230000028327 secretion Effects 0.000 abstract description 4
229940046168 CpG oligodeoxynucleotide Drugs 0.000 abstract description 3
230000022534 cell killing Effects 0.000 abstract description 2
102100037850 Interferon gamma Human genes 0.000 abstract 1
108010074328 Interferon-gamma Proteins 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000006698 induction Effects 0.000 description 22
230000002147 killing effect Effects 0.000 description 22
241000699670 Mus sp. Species 0.000 description 21
238000002347 injection Methods 0.000 description 21
239000007924 injection Substances 0.000 description 21
239000002609 medium Substances 0.000 description 15
238000011282 treatment Methods 0.000 description 15
238000012360 testing method Methods 0.000 description 14
210000004443 dendritic cell Anatomy 0.000 description 12
238000002560 therapeutic procedure Methods 0.000 description 12
238000012258 culturing Methods 0.000 description 11
239000002243 precursor Substances 0.000 description 11
238000002474 experimental method Methods 0.000 description 10
230000002601 intratumoral effect Effects 0.000 description 10
238000010253 intravenous injection Methods 0.000 description 10
102000000588 Interleukin-2 Human genes 0.000 description 9
108010002350 Interleukin-2 Proteins 0.000 description 9
229940046166 oligodeoxynucleotide Drugs 0.000 description 9
230000003248 secreting effect Effects 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 8
230000001464 adherent effect Effects 0.000 description 8
238000009169 immunotherapy Methods 0.000 description 8
210000002865 immune cell Anatomy 0.000 description 7
239000002504 physiological saline solution Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
229940076838 Immune checkpoint inhibitor Drugs 0.000 description 6
108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 6
102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 6
102000003812 Interleukin-15 Human genes 0.000 description 6
108090000172 Interleukin-15 Proteins 0.000 description 6
239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 6
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 6
229960004276 zoledronic acid Drugs 0.000 description 6
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
102000004388 Interleukin-4 Human genes 0.000 description 5
108090000978 Interleukin-4 Proteins 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000037396 body weight Effects 0.000 description 5
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000015788 innate immune response Effects 0.000 description 5
229940028885 interleukin-4 Drugs 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 5
210000003462 vein Anatomy 0.000 description 5
102100025137 Early activation antigen CD69 Human genes 0.000 description 4
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
102000017761 Interleukin-33 Human genes 0.000 description 4
108010067003 Interleukin-33 Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
229960001438 immunostimulant agent Drugs 0.000 description 4
239000003022 immunostimulating agent Substances 0.000 description 4
230000003308 immunostimulating effect Effects 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000035772 mutation Effects 0.000 description 4
208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
206010052015 cytokine release syndrome Diseases 0.000 description 3
230000034994 death Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
206010073071 hepatocellular carcinoma Diseases 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
231100000682 maximum tolerated dose Toxicity 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000005303 weighing Methods 0.000 description 3
GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 2
102400000888 Cholecystokinin-8 Human genes 0.000 description 2
101800005151 Cholecystokinin-8 Proteins 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
206010029350 Neurotoxicity Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010044221 Toxic encephalopathy Diseases 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000006838 adverse reaction Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000007135 neurotoxicity Effects 0.000 description 2
231100000228 neurotoxicity Toxicity 0.000 description 2
230000009437 off-target effect Effects 0.000 description 2
238000007427 paired t-test Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000005909 tumor killing Effects 0.000 description 2
206010048962 Brain oedema Diseases 0.000 description 1
239000012275 CTLA-4 inhibitor Substances 0.000 description 1
229940045513 CTLA4 antagonist Drugs 0.000 description 1
108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
206010050685 Cytokine storm Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102100039845 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-8 Human genes 0.000 description 1
101710112841 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-8 Proteins 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
108091008036 Immune checkpoint proteins Proteins 0.000 description 1
102000037982 Immune checkpoint proteins Human genes 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
239000012270 PD-1 inhibitor Substances 0.000 description 1
239000012668 PD-1-inhibitor Substances 0.000 description 1
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004721 adaptive immunity Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000011398 antitumor immunotherapy Methods 0.000 description 1
201000007201 aphasia Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000003139 biocide Substances 0.000 description 1
238000009534 blood test Methods 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000005138 cryopreservation Methods 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
239000002075 main ingredient Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000010827 pathological analysis Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940121655 pd-1 inhibitor Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000012795 verification Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Public Health (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Epidemiology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CN202211690866.0A 2022-03-02 2022-03-02 用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法 Pending CN116694568A (zh)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CN202211690866.0A CN116694568A (zh)	2022-03-02	2022-03-02	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN202210195028.XA CN114292813B (zh)	2022-03-02	2022-03-02	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法
CN202211690866.0A CN116694568A (zh)	2022-03-02	2022-03-02	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN202210195028.XA Division CN114292813B (zh)	2022-03-02	2022-03-02	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法

Publications (1)

Publication Number	Publication Date
CN116694568A true CN116694568A (zh)	2023-09-05

Family

ID=80978476

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN202210195028.XA Active CN114292813B (zh)	2022-03-02	2022-03-02	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法
CN202211690866.0A Pending CN116694568A (zh)	2022-03-02	2022-03-02	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CN202210195028.XA Active CN114292813B (zh)	2022-03-02	2022-03-02	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法

Country Status (2)

Country	Link
CN (2)	CN114292813B (fr)
WO (1)	WO2023165573A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114292813B (zh) *	2022-03-02	2022-11-08	北京市希波生物医学技术有限责任公司	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8207314B2 (en) *	2003-05-16	2012-06-26	Sanofi Pasteur Limited	Tumor antigens for prevention and/or treatment of cancer
CN1869206A (zh) *	2006-05-27	2006-11-29	大连理工大学	一种高效免疫活性细胞群制备及用于抗肿瘤的方法
WO2009131730A2 (fr) *	2008-01-31	2009-10-29	University Of Iowa Research Foundation	COMPOSITIONS IMMUNOGÈNES POUR L'ACTIVATION DE LYMPHOCYTES T γδ
AU2014310935B2 (en) *	2013-08-21	2019-11-21	CureVac SE	Combination vaccine
DK3117030T3 (da) *	2014-03-14	2022-06-27	Robert E W Hancock	Diagnosticering af sepsis
EP3137105A4 (fr) *	2014-04-30	2017-12-27	President and Fellows of Harvard College	Dispositifs de vaccin combiné et procédés de destruction de cellules cancéreuses
CN104651312A (zh) *	2015-02-06	2015-05-27	上海力沃生物科技有限公司	一种高效免疫活性细胞CpG-DCIK的制备方法及应用
CN105695403A (zh) *	2015-12-31	2016-06-22	深圳市中美康士生物科技有限公司	一种杀伤性免疫细胞的培养方法及其应用
US20170246311A1 (en) *	2016-02-26	2017-08-31	University Of Washington	Peptides for binding alternatively activated macrophages
CN107184973A (zh) *	2016-03-15	2017-09-22	中国医学科学院基础医学研究所	一种复合疫苗佐剂及其应用
EP3493833A1 (fr) *	2016-08-05	2019-06-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Utilisations immunothérapeutiques de cellules t régulatrices foxp3 + générées ex vivo
WO2018024895A1 (fr) *	2016-08-05	2018-02-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Utilisations immunothérapeutiques de lymphocytes t régulateurs foxp3+ générés ex vivo
KR102069670B1 (ko) *	2017-03-02	2020-01-23	단디바이오사이언스 주식회사	면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
WO2019160780A1 (fr) *	2018-02-16	2019-08-22	Wang tian xin	Méthodes et agents pour traiter des cellules tumorales et le cancer
CN110857315A (zh) *	2018-08-14	2020-03-03	许洋	一种治疗肿瘤的多肽药物、衍生物及其使用方法
WO2021087439A1 (fr) *	2019-11-02	2021-05-06	Figene, Llc	Administration intratumorale d'agents thérapeutiques cellulaires immunitaires
CN111500535B (zh) *	2020-04-30	2023-04-14	惠和生物技术(上海)有限公司	用于体外培养人自然杀伤细胞的方法和培养基
US20210393681A1 (en) *	2020-06-22	2021-12-23	Therapeutic Solutions International, Inc.	Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity
AU2021307416A1 (en) *	2020-07-13	2023-02-02	Oregon Health & Science University	Immunogenic constructs, compositions, and methods for inducing immune response
CN113430167A (zh) *	2021-07-19	2021-09-24	广州百暨基因科技有限公司	同时扩增γδT和NK的培养方法
CN114292813B (zh) *	2022-03-02	2022-11-08	北京市希波生物医学技术有限责任公司	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法

2022
- 2022-03-02 CN CN202210195028.XA patent/CN114292813B/zh active Active
- 2022-03-02 CN CN202211690866.0A patent/CN116694568A/zh active Pending
2023
- 2023-03-02 WO PCT/CN2023/079384 patent/WO2023165573A1/fr not_active Ceased

Also Published As

Publication number	Publication date
CN114292813A (zh)	2022-04-08
WO2023165573A1 (fr)	2023-09-07
CN114292813B (zh)	2022-11-08

Publication	Publication Date	Title
Patente et al.	2019	Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy
US12064446B2 (en)	2024-08-20	Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
Zhang et al.	2004	Mobilization of dendritic cell precursors into the circulation by administration of MIP-1α in mice
Curley et al.	2020	Immunomodulation of intracranial melanoma in response to blood-tumor barrier opening with focused ultrasound
EP2855668B1 (fr)	2018-12-26	Méthodes de fabrication de cellules immunosuppressives
JP7235259B2 (ja)	2023-03-08	Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
CN118750590A (zh)	2024-10-11	使用反义分子治疗癌症的方法和组合物
US20250361484A1 (en)	2025-11-27	Use of memory lymphocyte population in liver cancer treatment
CN116694568A (zh)	2023-09-05	用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法
JP6980650B2 (ja)	2021-12-15	進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法
JP2017520582A (ja)	2017-07-27	関節リウマチ治療のための間葉系間質細胞
US20240228964A9 (en)	2024-07-11	Highly Potent M-CENK Cells And Methods
US20250367235A1 (en)	2025-12-04	Systems and methods for modulating a cell phenotype
CN115518060A (zh)	2022-12-27	衣康酸及其衍生物在治疗白癜风药物上的应用及其治疗白癜风的药物
Hironaka et al.	2006	Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432
CN119776283B (zh)	2025-06-27	Car-t细胞培养方法及其在肿瘤治疗中的应用
CN115400204B (zh)	2025-07-04	趋化因子ccl23在制备乳腺癌免疫治疗药物中的应用
CN119372143B (zh)	2025-03-28	细胞因子组合、培养基、肿瘤特异性的t细胞群及其应用
CN109793889B (zh)	2023-11-10	一种肿瘤疫苗及其制备方法
CN120078759A (zh)	2025-06-03	苏拉明及其衍生物和药物组合物的应用
CA2340085A1 (fr)	2000-02-24	Cellules presentatrices d'antigenes modifiees genetiquement, exprimant un groupe d'antigenes, et leurs methodes d'utilisation
CN119235861A (zh)	2025-01-03	通佐溴胺在制备用于治疗微环境免疫功能缺陷型疾病的药物中的用途
CN120683048A (zh)	2025-09-23	外周血源cik细胞制备方法及其在肿瘤抑制中的用途
CN102166347A (zh)	2011-08-31	一种白细胞介素-12的药物新用途
HK40023269B (en)	2023-04-28	Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd

Legal Events

Date	Code	Title	Description
2023-09-05	PB01	Publication
2023-09-05	PB01	Publication
2023-09-22	SE01	Entry into force of request for substantive examination
2023-09-22	SE01	Entry into force of request for substantive examination
2023-12-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40092200 Country of ref document: HK